Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

NCT: NCT04999046 · COMPLETED

NCT IDNCT04999046
StatusCOMPLETED
Start Date2021-10-07
Completion2024-07-31

Brief Summary

To evaluate the safety and efficacy of using NaviFUS™ system in patients with drug resistant epilepsy

Frequently Asked Questions

What is NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy?

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy is a clinical trial registered under NCT04999046. Current status: COMPLETED.

What is the status of NCT04999046?

The current status of NCT04999046 (NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy) is: COMPLETED.

When did NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy start?

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy started on 2021-10-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑